The Use of Fluoroquinolones for Tuberculosis in Victoria between 2011 and 2016

Table 1

Characteristics of cases who received moxifloxacin versus those who did not receive moxifloxacin.

Factors	Moxi	(%)	Non-Moxi	(%)
Number	276		1992
Age	44.78		38.5
Sex (male)	150	(54.3)	1129	(56.7)
Site of disease
Pulmonary	165	59.8	1182	59.3
Meningeal	12	4.3	9	0.5
Central Nervous System	2	0.7	4	0.2
Ocular	10	3.6	12	0.6
Other extra-pulmonary	87	31.5	786	39.4
Country of origin
Australian	22	8.0	219	11.0
Overseas	254	92.0	1773	89.0
HIV status
Positive	5	1.8	32	1.6
Negative	67	24.3	328	16.5
Unknown	204	73.9	1632	81.9
Diagnosis method
Culture	217	78.6	1521	76.3
Histological	13	4.7	161	8.1
PCR/NAT	19	6.9	116	5.8
Radiological	9	3.3	126	6.3
Clinical	17	6.2	58	2.9
Microscopic Examination	1	0.4	10	0.5
Sensitivities - Of culture positive cases
Fully sensitive	148	68.2	1410	92.6
MDRTB	39	18.0	0	0.0
XDRTB	2	0.9	0	0.0
Other resistance patterns	26	12.0	103	6.8
Isoniazid Resistance	24	92.3	97	94.2
Rifampicin resistance	1	3.8	0	0.0
Pyrazinamide resistance	1	3.8	2	1.9
Ethambutol resistance	0	0.0	3	2.9
Other agents	0	0.0	1	1.0
Sensitivity results pending	2	0.9	9	0.6